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The potential of resveratrol to mimic beneﬁcial eﬀects of calorie restriction (CR) was investigated. We compared the eﬀects of
both CR (70% of ad libitum energy intake) or resveratrol (2g/kg or 4g/kg food) on high-fat diet-induced obesity and fatty
liver formation in C57Bl/6J mice, and we examined their eﬀects on calorimetry, metabolic performance, and the expressions
of inﬂammatory genes and SIRT proteins. We found that resveratrol with 4g/kg dose partially prevented hepatic steatosis and
hepatocyte ballooning and induced skeletal muscle SIRT1 and SIRT4 expression while other examined parameter were unaﬀected
by resveratrol. In contrast, CR provided superior protection against diet-induced obesity and fatty liver formation as compared
to resveratrol, and the eﬀects were associated with increased physical activity and ameliorated adipose tissue inﬂammation. CR
increased expressions of SIRT3 in metabolically important tissues, suggesting that the beneﬁcial eﬀects of CR are mediated, at least
in part, via SIRT3-dependent pathways.
1.Introduction
Obesity, the worldwide increasing problem, associates with
several metabolic abnormalities and increases the risk of
chronic diseases such as type 2 diabetes, cardiovascular
diseases, and certain forms of cancer [1]. Obesity is also
the major risk factor for nonalcoholic fatty liver disease
(NAFLD), a disease spectrum that includes hepatic steatosis,
steatohepatitis, ﬁbrosis, and liver cirrhosis [2, 3]. The
fatty liver has been shown to be insulin resistant and to
overproduce glucose, VLDL, CRP, and coagulation factors
leading to hyperglycemia and lipid disorders [4].
While excessive calorie intake and subsequent obesity are
associated with several health problems, calorie restriction
(CR) with adequate nutrition ameliorates obesity-induced
metabolic disturbances, and it has also been proven to
be an eﬀective treatment for NAFLD [5, 6]. In rodents,
CR extends lifespan by up to 50% [7]. The mechanisms
underlyingthebeneﬁcialeﬀectsofCRisnotwellunderstood;
however, accumulating evidence indicates an important role
for sirtuins, a highly conserved family of NAD+-dependent
enzymes regulatinglifespan in lower organisms,asmetabolic
sensors and mediators of the cellular eﬀects of CR [8].
At present, seven sirtuins (SIRT1–SIRT7) have been
discovered from mammals, and of them nuclear located
SIRT1 is the closest homologue of Sir2 protein that regulates
the aging processes and mediates the CR-induced extension
of lifespan in lower organisms [9, 10]. SIRT1 has been shown
to increase cellular stress resistance and genomic stability,
and it regulates cellular senescence and energy metabolism2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
via deacetylation of the target proteins such as p53, FOXO
transcription factors, and PGC-1α [10, 11]. It has been
claimed that the beneﬁcial cellular eﬀects of CR are largely
mediated by induction of SIRT1 whereas considerably less is
known about the other members of sirtuin family.
Three sirtuins SIRT3–SIRT5 are primarily located in
mitochondrial matrix [12]. Interestingly, crosstalk has been
shown between mitochondrial and nuclear sirtuins, and
SIRT4 has been shown to regulate fatty acid oxidation
in hepatocytes through SIRT1-dependent manner [13]. In
addition, SIRT3 regulates mitochondrial function, thermo-
genesis,andmitochondrialfattyacidoxidationbypromoting
expression of mitochondrial genes [14], and by regulating
the acetylation levels of metabolic enzymes, including acetyl
coenzyme A synthetase 2 (AceCS2) [15, 16], and long-chain
acyl coenzyme A dehydrogenase (LCAD) [17]. Moreover,
SIRT3 regulates ATP synthesis by deacetylating several
proteins in mitochondria electron transport Complex I [18].
SIRT3 is the only sirtuin with a reported association with the
humanlifespan[19,20],makingitaninterestingnoveltarget
for energy homeostasis.
As weight loss and subsequent body weight mainte-
nance has been shown to be very diﬃcult for obese indi-
viduals and as the compliance for low-calorie diets is of-
ten very poor in long-term clinical trials, several sirtuin-
activating compounds (STACs) mimicking the beneﬁcial
eﬀects related to CR have been developed recently [21].
Resveratrol (3,5,4-trihydroxystillbene), a natural polyphe-
nolic compound derived from the grapes, was one of the
ﬁrst STACs that was shown to extend yeast lifespan through
an SIRT1-dependent mechanism [21]. More recently, the
beneﬁcial eﬀects of resveratrol were reported in mammalian
cells [22]. In vivo studies with experimental obesity models
have revealed that resveratrol improves health and prevents
premature mortality associated with obesity [23, 24]. It is
generallybelievedthatresveratrolismimickingthebeneﬁcial
eﬀects of CR mainly in an SIRT1-dependent manner [25].
The aim of the present study was to investigate the
potential of long-term resveratrol supplementation to mimic
the beneﬁcial eﬀects of CR without reducing calorie intake.
We compared the eﬀects of CR and resveratrol on diet-
induced obesity and fatty liver formation. We also examined
the eﬀects of CR and resveratrol on metabolic performance,
adipocyteinﬂammatoryresponse,andtissue-speciﬁcprotein
expressions of SIRT1 and mitochondrial sirtuins SIRT3 and
SIRT4. Lean mice receiving a standard low-fat diet served as
healthy controls, and data from these animals were used as
reference values in the present study.
2.MaterialsandMethods
2.1. Animals and Diets. Seven-week-old male C57Bl/6J
(Charles River, Germany) mice were housed three, four, or
ﬁve mice in a cage in a standard experimental laboratory,
illuminated from 07.00 to 19.00, at temperature 22 ± 1◦C.
TheprotocolswereapprovedbytheAnimalExperimentation
Committee of the University of Helsinki (number 07–
06589), Finland, and the principles of laboratory animal care
(NIH publication no. 85–23, revised 1985) were followed.
The mice had free access to tap water during experiment.
After a one-week acclimatization period the mice (initial
body weight 21.3 ± 0.1g) were divided to ﬁve groups for
15 weeks: (1) HFD group (n = 18) received high-fat
diet (60% of energy from fat, D12492, Research Diet Inc.;
USA) ad libitum, (2) CR group (n = 18) received HFD
and was kept under calorie restriction (energy intake 70%
of ad libitum intake), (3) HFD + R2 group (n = 19)
received HFD mixed with low-dose resveratrol (2g/food kg;
Orchid Chemicals & Pharmaceuticals Ltd., India), (4) HFD
+R 4g r o u p( n = 19) received HFD mixed with high-dose
resveratrol (4g/kg food), (5) LFD group (n = 18) received
low-fat diet (10% of energy from fat, D12450B, Research
Diet Inc., USA) ad libitum. The powered high-fat diet was
moistened with tap water 100mL/kg and low-fat diet with
tap water 200mL/kg, packed in one-day portions and stored
at −20◦C.
2.2. Body Weight and Body Fat percentage Measurements.
The food consumption was monitored daily and the body
weight three times per week by using a standard table scale
(Mettler-Toledo, Columbus, USA). The body fat percentage
was analyzed from anesthetized mice by magnetic resonance
imaging (MRI; Oxford Instrument, Oxford, UK) [26].
2.3. Calorimetry and Metabolic Performance. The eﬀects of
resveratrol and CR on metabolic performance, physical
activity, drinking, and feeding behaviour were analysed
by housing six mice from each group in a home cage-
based monitoring system for laboratory animals (LabMaster
TSE System, Bad Homburg, Germany). LabMaster system
combines various sensors that monitor simultaneously, non-
invasively, and continuously both in light and dark phases
several physiological and behavioural parameters for each
animal. During the experiment mice were housed in one-
mouse cage after a one-week acclimatization period. The
experiment was conducted during the study weeks 12–15.
The measuring time was 100 hours consisting of 52 hours
light phase and 48 hours dark phase. The drinking and feed-
ing behaviour of the mice was measured by high-precision
sensors attached to the top of the cage lids. The indirect
calorimetry system is an open-circuit measuring system,
which allowed determination of mice O2 consumption, CO2
production, respiratory exchange rate, and heat production.
The infrared light-beams sensors surrounding the cage
detected mice physical activity comprising ambulatory, ﬁne,
and rearing movements.
2.4.TissueSamplePreparation. Attheendofthecalorimetric
measurements the mice were decapitated. Liver, muscle
(musculus quadriceps femoris), and subcutanic, epididymal,
abdominal, and perirenal fat samples were dissected, washed
with saline, blotted dry, and weighted. Samples were snap-
frozen in liquid nitrogen and stored at −80◦C until assayed.
2.5.LiverHistology. Formalin-ﬁxed,paraﬃn-embeddedliver
sections (4μm) were stained with H&E. The stained sections
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Figure 1: Development of body weight during 12 study weeks (a) and body fat percentage after 12 study weeks (b, n = 10/group). ∗P<0.05
compared to HFD/HFD + R2/HFD + R4, †P<0.05 compared to LFD. Data is presented as mean ± SEM.
Table 1: Fat pad weights (g).
HFD (n = 12) HFD + R2 (n = 13) HFD + R4 (n = 13) CR (n = 12) LFD (n = 12) P value
Subcutaneous 0.822 ± 0.073 0.752 ± 0.065 0.770 ± 0.064 0.204 ± 0.016∗/† 0.368 ± 0.034∗ P<0.001
Abdominal 0.809 ± 0.105 0.746 ± 0.083 0.732 ± 0.096 0.181 ± 0.019∗ 0.379 ± 0.040∗ P<0.001
Epididymal 2.406 ± 0.151 2.509 ± 0.124 2.463 ± 0.131 0.723 ± 0.067∗/† 1.348 ± 0.120∗ P<0.001
Perirenal 0.678 ± 0.025 0.666 ± 0.035 0.614 ± 0.040 0.182 ± 0.019∗/† 0.387 ± 0.034∗ P<0.001
Total 4.714 ± 0.262 4.673 ± 0.236 4.579 ± 0.256 1.290 ± 0.115∗/† 2.482 ± 0.202∗ P<0.001
Visceral 3.893 ± 0.215 3.921 ± 0.185 3.809 ± 0.200 1.085 ± 0.101∗/† 2.114 ± 0.183∗ P<0.001
Data is presented as mean ± SEM.
∗P<0.05 compared to HFD/HFD + R2/HFD + R4, †P<0.05 compared to LFD.
ventional light microscope in a “blinded” fashion. The sam-
ples were subjected to a semiquantitative histological anal-
ysis using the nonalcoholic steatohepatitis (NASH) Clinical
Research Network scoring system for NAFLD with slight
modiﬁcations for mice samples [27].
2.6. RNA Isolation and Gene Expression Analysis by Quan-
titative Real-Time Reverse Transcriptase PCR (qRT-PCR)
Assay. TotalRNAwasisolatedbyTRIzolreagent(Invitrogen,
Carlsbad,CA,USA).TheconcentrationandintegrityofRNA
samples were analyzed by spectrophotometer (absorbance
260 and 280nm). RNA samples were treated with DNAse
I (deoxyribonuclease 1, Sigma Chemicals, St. Louis, MO)
and 1μg of total RNA was reverse transcribed to cDNA by
ImProm-II Reverse Transcription System (Promega, Madi-
son, USA). The mRNA expression analysis was performed
using Light-Cycler quantitative RT-PCR instrument (Roche
Diagnostics, Neuilly-Sur-Seine, France). The samples were
ampliﬁed with FastStart DNA Master SYBR Green 1 (Roche
diagnostics) in the presence of 0.5μM of the following
primers: adiponectin forward GTATCGCTCAGCGTTC and
reverse GTCGTTGACGTTATCTGC; Cd68 forward CCC-
GAGTACAGTCTACCandreserveGTTGATTGTCGTCTG-
CG; leptin forward AGACCGGGCAAGAGTG and reverse
GCCATAGTGCAAGGTT; MCP-1 (monocyte chemoat-
tractant protein 1) forward CGGAACCAAATGAGATCAG
and reverse TCACAGTCCGAGTCAC; PAI-1 (plasminogen
activator inhibitor 1) forward ACAGCCTTTGTCATCTCA-
GCCandreverseCCGAACCACAAAGAGAAAGGA;visfatin
forward AGAGTGCTACTGGCTTACC and reverse CTT-
TCCCCCACGCTGT and 18S forward ACATCCAAGGAA-
GGCAGCAG and reverse TTTTCGTCACTACCTCCCCG.
The quantities of the PCR products were quantiﬁed with
an external standard curve ampliﬁed from puriﬁed PCR
product. All the values were normalized to 18SmRNA levels.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Cumulative respiratory exchange ratio (RER, a) CO2 (b), cumulative ambulatory (c), total activity (d), and cumulative rearing (e)
of mice. ∗P<0.05 compared to HFD/HFD + R2/HFD + R4, ‡P<0.05CR,†P<0.05 compared to LFD, §P<0.05 compared to HFD + R2,
¤P<0.05 compared to HFD + R4.
2.7. Protein Isolation and Immunoblotting Analysis. Pro-
teins from perirenal fat samples were isolated with cell
extraction buﬀer (Invitrogen, Carlsbad, CA, USA) and
complete protease inhibitors (Roche Diagnostics, Neuilly-
Sur-Seine, France). Proteins from liver and muscle samples
were isolated with lysis buﬀer (NaCl 136mM, Na2HPO4
8mM, K Cl 2.7mM, KH 2PO4 1.46mM, Tween 20 0.001%
and complete protease inhibitors (Roche Diagnostics)).
In immunoblotting 20μg of total protein were used and
protein were separated by 8% sodium dodecyl sulphate-
polyacrylamidegelelectrophoresis.Proteinsweretransferred
to a polyvinyldiﬂuoride membrane (Immobilon-FL, Mil-
lipore, Bedford, MA, USA) and blocked for 2h in 5%
non-fat milk-TBS-0.05% Tween 20 buﬀer. The membranes
were probed with anti-SIR2α (Upstate, Lake Placid, N.Y.,
USA) at dilution 1:1500, anti-SIRT3 (Abcam, Cambridge,
UK) at dilution 1:500 and anti-SIRT4 (Abcam) at dilu-
tion 1:1000 in blocking buﬀer. Alpha-tubulin (Abcam) at
dilution 1:2000 was used as a loading control. Horse-
radish peroxidase-conjugated anti-rabbit secondary anti-
body (Chemicon, Temecula, CA, USA) was used at dilution
1:5000. The localization of horse-radish peroxidase was
detected with Amersham ECL Plus (GE Healthcare, Little
Chalfont, UK) according to instructions of manufacturer
and visualized by FLA-9000 ﬂuorescent image analyzer
(FUJIFILM Corp., Tokyo, Japan).J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 3:TheadiposetissuemRNAexpressionofadiponectin(a),Cd68(b),leptin(c),MCP-1(d),PAI-1(e),andhepaticmRNAexpression
of visfatin (d) (n = 12 in HFD/CR/LFD groups and n = 13 in HFD + R2/HFD + R4 groups). ∗P<0.05 compared to HFD/HFD + R2/HFD
+R 4 ,#P<0.05 compared to HFD, †P<0.05 compared to LFD §P<0.05 compared to HFD + R2, ¤P<0.05 compared to HFD + R4. Data
is presented as mean ± SEM.
2.8. Statistical Analysis. Data are presented as mean ± SEM.
Statistically signiﬁcant diﬀerences in mean values were tested
byone-wayANOVAfollowedbytheStudent-Newman-Keuls
test. Analyses in a function of time were done by two-way
ANOVA followed by the Bonferroni test. P values below 0.05
were considered statistically signiﬁcant. GraphPad Prism,
version 4.02 (GraphPad Software, Inc., San Diego, CA, USA)
was used for the statistical analyses.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 2: Food, energy, and water intakes of mice.
HFD (n = 6) HFD + R2 (n = 6) HFD + R4 (n = 6) CR (n = 6) LFD (n = 6) P value
Food consumption (g/day) 2.98 ± 0.20 2.90 ± 0.13 2.86 ± 010 2.16 ± 0.07∗ 3.86 ± 0.18∗/‡ P<0.0001
Water consumption (mL/day) 2.16 ± 0.11 1.87 ± 0.10‡ 1.83 ± 0.10‡ 2.30 ± 0.07 2.61 ± 0.14∗ 0.0001
Energy intake (kcal/day) 14.17 ± 0.95 13.78 ± 0.63 13.55 ± 0.47 10.27 ± 0.35∗/† 14.85 ± 0.68 0.0004
Data is presented as mean ± SEM.
∗P<0.05 compared to HFD/HFD + R2/HFD + R4.
†P<0.05 compared to LFD.
‡P<0.05 compared to CR.
3. Results
3.1. Body-Weight Gain. Body weight in mice fed with
HFD increased steadily during the whole follow-up period
(Figure 1(a)). Neither low-dose nor high-dose resveratrol
inﬂuencedbody-weightgaininmicefedwithHFD.Thebody
weight in mice fed with LFD increased in parallel with HFD
during the ﬁrst 40 days, but thereafter remained markedly
lower compared to HFD groups. There was only a modest
increase in body weight in mice kept under CR, the ﬁnal
body weight being markedly lower compared with all other
treatment groups.
3.2. Body Fat Content. The body fat percentage measured by
MRI was markedly higher in mice fed with HFD compared
to LFD group (Figure 1(b)). Resveratrol treatments did not
inﬂuence body fat percentage in mice fed with HFD. In
contrast, CR decreased body fat percentage to level found in
LFD-treated mice.
Neither resveratrol dosages decreased fat pad weights in
micefedwithHFDwhereastheweightoffatpadsinLFDand
CR groups were signiﬁcantly lower (Table 1). The weight of
diﬀerent fat pads in CR group was lower compared to LFD
except in abdominal fat.
3.3.Food,Energy,andWaterIntakes. Thefoodintakeinmice
fed with LFD was greater compared with other treatment
groups (Table 2). However, there was no diﬀerence in
energy intake between LFD and HFD groups fed ad libitum
(Table 2). Resveratrol treatments did not inﬂuence food or
energy intake. The food and energy intakes in mice under
CR were approximately 70% of the ad libitum control values.
The water intake in mice fed with LFD was higher compared
with the other treatment groups (Table 2). Interestingly both
low-dose resveratrol and high-dose resveratrol treatments
decreased water intake whereas CR did not inﬂuence water
intake.
3.4. Metabolic Performance and Physical Activity. The cumu-
lative respiratory exchange ratio (RER) and CO2 production
in mice fed LFD was higher compared to other groups
(Figures 2(a) and 2(b)). Neither resveratrol treatments nor
CR inﬂuenced RER or CO2 production. The cumulative O2
and heat production did not diﬀer between the study groups
(data not shown).
The cumulative ambulatory movements, total activity,
and cumulative rearing were increased in mice kept under
CR (Figures 2(c)–2(e)). The cumulative ﬁne movements
did not diﬀer between study groups (data not shown).
Resveratrol treatments tended to decrease total activity and
cumulative rearing; however, the diﬀerence did not reach
statistical signiﬁcance (Figures 2(d) and 2(e)).
3.5. Liver Histology. The liver histology in mice fed with
HFD showed prominent steatosis (Table 3). Furthermore,
hepatocyte ballooning indicating activity of hepatocyte
degeneration was found in mice fed with HFD (Table 3).
Merely moderate lobular inﬂammation was seen in all
study groups (Table 3). Complete absence of steatosis and
hepatocyte ballooning was seen in the CR and the LFD
groups. Resveratrol, when given at higher dosage, tended to
ameliorate steatosis and hepatocyte ballooning.
3.6. Adipose Tissue Inﬂammation and Hepatic mRNA Expres-
sions of Visfatin and Mitochondrial Biogenesis Markers. CR
increased adipose tissue adiponectin mRNA expression and
eﬀectively decreased the mRNA expressions of inﬂammatory
markers Cd68, leptin MCP-1, and PAI-1 in the adipose
tissue (Figures 3(a)–3(e)). In addition, mice fed with LFD
showed lower mRNA expression of Cd68, leptin, and MCP-1
(Figures 3(b)–3(d)). Neither low-dose resveratrol nor high-
doseresveratrolinﬂuencedthemRNAexpressionsofadipose
tissue inﬂammatory markers (Figures 3(a)–3(e)). There was
no diﬀerence between HFD and LFD groups in the mRNA
expressions of visfatin in liver (Figure 3(f)). CR markedly
upregulated the visfatin mRNA expression but neither the
low- or high-dose of resveratrol did not inﬂuence visfatin
mRNA expression (Figure 3(f)). There were no statistical
signiﬁcant diﬀerences between study groups in biogenesis
markers PGC-1α, Nrf-1, and Tfam mRNA expressions in
liver (data not shown).
3.7. Tissue SIRT1, SIRT3, and SIRT4 Protein Expressions.
Mice fed with HFD showed decreased SIRT1 expression in
the liver as compared with LFD whereas no diﬀerence was
found in skeletal muscle or adipose tissue SIRT1 expression
(Figures 4(a)–4(c)). There was no diﬀerence between HFD
and LFD groups in SIRT3 protein expression in liver, skeletal
muscle, and adipose tissue (Figures 4(d)–4(f)). Adipose
tissue SIRT4 protein expression was undetectable and no
diﬀerence was seen between LFD and HFD group in SIRT4
protein expression in liver and skeletal muscle (Figures 4(g)
and 4(h)).
CR increased SIRT1 expression in the liver and skeletal
muscle (Figures 4(a) and 4(b)) and SIRT3 protein expressionJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 7
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Figure 4: Protein expression of SIRT1 in liver (a), skeletal muscle (b), and adipose tissue (c), protein expression of SIRT3 in liver (d),
skeletal muscle (e), and adipose tissue (f), and protein expression of SIRT4 in liver (g) and skeletal muscle (h) (n = 6/group, analyzed twice).
∗P<0.05 compared to HFD/HFD + R2/HFD + R4, #P<0.05 compared to HFD, †P<0.05 compared to LFD, §P<0.05 compared to HFD
+R 2 ,a n d¤P<0.05 compared to HFD + R4. Data is presented as mean ± SEM.
in liver, skeletal muscle, and adipose tissue (Figures 4(d)–
4(f)). In addition, CR increased SIRT4 protein expression in
skeletal muscle (Figure 4(h)).
High-dose resveratrol increased SIRT1 expression in
the skeletal muscle (Figures 4(b)) and tended to increase
liver SIRT1 expression (Figure 4(a)). Furthermore, high-
dose resveratrol increased SIRT4 protein expression in
skeletal muscle and tended to increase liver SIRT1 expression
(Figure 4(h)). Neither resveratrol dosages inﬂuenced SIRT3
expression (Figures 4(d)–4(f)).
4. Discussion
We compared the eﬀects of calorie restriction (CR) and
resveratrol supplementation on diet-induced obesity and
fattyliverformationbyusingC57Bl/6Jmicefedwithhigh-fat
dietasmodelofexperimentalobesity. Theimportant ﬁnding
of the present study was that neither low-dose nor high-
dose resveratrol treatment inﬂuenced energy intake, body
weight gain, body fat percentage, or metabolic performance.
A modest protection against hepatic steatosis and hepatocyte
ballooning was found by high-dose resveratrol treatment. In
contrast, CR completely prevented development of obesity
and fatty liver formation as well as adipocyte tissue inﬂam-
matory response indicating superior protection as compared
to resveratrol.
Resveratrolhasbeenwidelyusedtomimicthephysiolog-
ical eﬀects of CR [25] and to counteract the noncompliance
for low-calorie diets often observed in clinical trials. Recent
studies have demonstrated that CR induces SIRT1 [28, 29]8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 3: Incidences of the observed histopathological lesions in liver.
HFD HFD + R2 HFD + R4 CR LFD
Number of samples 10 10 10 10 10
Steatosis grade
(degree/description)
3/>66% 20 0 0 0
2/34–66% 55 3 0 0
3/5–33% 22 5 0 0
0/<5% 13 2 1 0 1 0
Lobular inﬂammation
(degree/description)
2/2–4 foci/20x optical
ﬁeld
10 0 0 0
1/<2 foci/20x optical
ﬁeld
58 5 4 3
0/none 42 5 6 7
Hepatocyte ballooning
(degree/description)
2/moderate, marked 30 0 0 0
1/mild, few 24 2 0 0
0/none 56 8 1 0 1 0
Fibrosis score
(degree/description)
0/none 10 10 10 10 10
a key regulator of cellular metabolism whereas resveratrol
activates SIRT1 enzyme through binding to the active site
of SIRT1 enzyme [21]. In the present study the resveratrol
dosage and route of administration (2 or 4g/kg food) was
based on previous study by Lagouge and coworkers [24]
demonstrating improvement of mitochondrial function and
protection against metabolic disease in experimental obesity.
Based on our calorimetric measurements and food intake
recordings the above-mentioned resveratrol diet concentra-
tions provided 135mg/kg and 282mg/kg daily resveratrol
dosages,respectively.Surprisingly,wewereunabletoconﬁrm
any statistically signiﬁcant reduction in body weight or
adiposity in our 15-week follow-up study although a modest
trend toward slightly lower body weight was noticed both
in mice fed with low-dose and high-dose resveratrol. We
cannot exclude the possibility that higher resveratrol dosage
or longer treatment period is needed for preventing weight
gain. Even though resveratrol has been shown to produce a
modest decrease in body weight also in rats fed a high-fat
diet [30] ,s e v e r a ls t u d i e sh a v eb e e nu n a b l et oc o n ﬁ r mt h e
beneﬁcial eﬀects of resveratrol on body weight and obesity
[23, 31]. Baur et al. [23] showed recently that low-dosage
resveratrol treatment (about 20mg/kg) increases survival of
high-fat-fed mice without reducing body weight.
Nonalcoholic fatty liver disease (NAFLD) represents a
wide variety of diseases ranging from hepatocellular steatosis
through steatohepatitis to ﬁbrosis and irreversible cirrhosis
[3]. Both NAFLD as well as chronic subinﬂammatory state
caused by the release of adipokines from white adipose
tissue are strongly associated with obesity, type 2 diabetes,
and development of cardiovascular diseases [3, 32]. With
assessment of obesity-induced fatty liver formation, we
relied on previously published and validated histological
scoring system [33, 34] comprising histological features
of which four are evaluated semiquantitatively, namely,
steatosis, lobular inﬂammation, hepatocellular ballooning,
and ﬁbrosis. In the present study, the steatotic change was
most commonly observed in the acinar zones 2 and 3,
thus resembling the adult human pattern [34]. Fibrosis
and inﬂammation are common features in human forms
of NAFLD; however, in diet-induced obese mice they were
practically absent. Although the aforementioned scoring
system is developed to detect NAFLD in clinical trials [33],
webelieveitisalsosuitableforscreeningfattyliverformation
in experimental obesity. We here report that CR almost com-
pletely prevented fatty liver formation whereas resveratrol
produced only a modest protection against hepatic steatosis
and hepatocyte ballooning. These ﬁndings indicate superior
protection against obesity-induced fatty liver formation by
CR compared to resveratrol.
Chronic inﬂammation in the adipose tissue plays an
important role in the development of obesity-related insulin
resistance [35–37]. In the present study we demonstrated
that CR decreased MCP-1, CD68, leptin, and PAI-1 mRNA
expressions in the adipose tissue as compared to obese mice
fedadlibitum.Furthermore,CRinducedadiponectinmRNA
expression in adipose tissue. These ﬁndings indicate that CR
exerts anti-inﬂammatory eﬀects. Neither low-dose nor high-
doseresveratroltreatmentinﬂuencedinﬂammatoryresponse
in the adipose tissue.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 9
In agreement with previous studies [38–40], we here
report that CR induced physical activity. SIRT1 is suggested
to be required for increased physical activity of CR mice, as
SIRT1 knock-out mice do not respond to CR with increased
physical activity [41]. Consistently, we noticed marked
increases in skeletal muscle and liver SIRT1 expression in
mice kept under CR. Even thought the higher dose of resver-
atrol induced SIRT1 protein in skeletal muscle, resveratrol
was unable to induce physical activity, and it tended to
even decrease physical activity. This is in line with previous
s t u d yb yL a g o u g ee ta l .[ 24] demonstrating that resveratrol
decreases ambulatory locomotor activity and number of
rears even thought improvement in neuromuscular function
was detected. Nevertheless, the reason for the lower physical
activity is unclear and needs further studies.
CR induced SIRT3 protein expression in liver, skeletal
muscle, and adipose tissue suggesting that the metabolic
beneﬁts of CR are regulated also via a SIRT3-dependent
manner. Both SIRT1 and SIRT3 are NAD+-dependent
deacetylases, and the changes in NAD+ concentration can
regulate their activity. Overexpression of visfatin (also called
Nampt), which catalyze ﬁrst and the rate-limiting step in
NAD+ biosynthesis from NAM, can markedly induce SIRT1
and SIRT3 activity [42, 43]. We showed higher expression
of visfatin in the CR group in liver which can also explain
the higher SIRT1 and SIRT3 protein expression in liver. The
inability of resveratrol to induce both visfatin and SIRT3
in metabolically important tissues can explain, at least in
part, the ineﬀectiveness of resveratrol to mimic CR mediated
health beneﬁts.
Interestingly, high-dose resveratrol treatment and to a
lesser extent CR increased SIRT4 protein expression in
the skeletal muscle. It has been shown that SIRT4 is
localized to mitochondria and mediates ADP-ribosylation
of protein substrates [12]. Depletion of SIRT4 increases
insulin secretion by modulation of glutamate dehydrogenase
activity in pancreatic β-cells [44]. In addition, a recent study
has provided evidence that SIRT4 depletion improves fatty
acid oxidation in hepatocytes in a SIRT1-dependent manner
[13]. Even thought in muscle cells SIRT4 depletion has been
shown to improve mitochondrial function [13], the role of
SIRT4 in skeletal muscle metabolism is still unknown and
needs further studies.
5. Conclusion
Using diet-induced obese mice as model of experimental
obesity we demonstrated superior protection against diet-
induced obesity and fatty liver formation by CR as compared
to oral resveratrol supplementation. The present study also
supports the notion that the beneﬁcial metabolic eﬀects
of CR are mediated, at least in part, via SIRT3-dependent
pathways.
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